Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Bioequivalence Study of JTE-052 New Drug Product vs JTE-052 Ointment 0.5% in Atopic Dermatitis
jRCT2031230713Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of delgocitinib in atopic dermatitis (AD) (2 arms), sponsored by Japan Tobacco. Primary endpoint: Percent change in mEASI score from Week 0 at end of treatment. Started Apr 2024; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230713.